Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22195036 | 0.83 | CYP2C9 (0.67) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL22191578 | 0.82 | CYP2C9 (0.65) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| Lithium Ion SCHEMBL30718122 | 0.81 | CYP2C9 (0.63) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| Lithium Ion SCHEMBL30718124 | 0.81 | CYP2C9 (0.63) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL10045022 | 0.80 | SMN1; SMN2 (0.52) | CYP2C9NPC1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL31434811 | 0.79 | CYP2E1 (0.60) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL27163520 | 0.79 | CYP2A6 (0.72) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL10162470 | 0.79 | CYP2A6 (0.72) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL19080614 | 0.78 | CYP2C9 (0.67) | CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL24461541 | 0.77 | POLB (0.43) | NPC1ALDH1A1SMN1; SMN2KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275739-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-05-02 | — | — | US | disclosed |
| US-11845753-B2 | Inhibitors of menin-mll interaction | BIOMEA FUSION, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220024936-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2022-01-27 | — | — | US | disclosed |
| US-11174263-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3906029-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Biomea Fusion, LLC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20200255434-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2020-08-13 | — | — | US | disclosed |
| WO-2020142559-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275739-B2 | Inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2C9 4639/4885CYP2C19 4605/4885CYP2E1 4419/4885 |
| US-11174263-B2 | Inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2C9 4739/4885CYP2C19 4725/4885CYP2E1 4639/4885 |
| US-20200255434-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2C9 4639/4885CYP2C19 4605/4885CYP2E1 4419/4885 |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2C9 4639/4885CYP2C19 4605/4885CYP2E1 4419/4885 |
| US-20220024936-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2C9 4639/4885CYP2C19 4605/4885CYP2E1 4419/4885 |
| US-11845753-B2 | Inhibitors of menin-mll interaction | MLLT1, MEN1, MLLT3 | CYP2C9 4639/4885CYP2C19 4605/4885CYP2E1 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.